Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry

Inclusion Criteria

• •Eligible to receive chemotherapy and endocrine therapy as defined by a good Karnofsky index (≥80) and no hematologic, cardiologic or hepatic contraindications, nor any impeding comorbidity
• •Informed consent form signed on the same day or before enrollment
• •≥ 18 years of age at time of consent Per study arm
• •Histologically proven invasive stage I and II breast cancer and Hormone Receptor positive (ER+ PR-, ER- PR+ or ER+ PR+) according to local standards \& HER2 negative: IHC 0-1+, or FISH or other ISH non-amplified (locally assessed)
• •IMPACt study; version 1 2015 September 1 Page 10 Axillary lymph node status: 0-3 involved (macro metastases i.e. \>2mm OR micro metastases i.e. \>0.2-2mm)
• •OR
• •Histologically proven invasive T1a or T1b breast cancer \& Hormone receptor negative (ER- and PR-) according to local standards \& HER2 negative: IHC 0-1+, or FISH or other ISH non-amplified (locally assessed)
• •\& Axillary lymph node status: 0-1 involved (macro metastases i.e. \>2mm OR micro metastases i.e. \>0.2-2mm)
• •OR
• •Histologically proven invasive T1a or T1b breast cancer
• •\& Hormone receptor negative or positive (ER-PR-, ER+PR-, ER-PR+, ER+PR+) according to local standards
• •\& HER2 positive: IHC 3+, or FISH or other ISH amplified (locally assessed)
• •\& Axillary lymph node status: 0-1 involved (macro metastases i.e. \>2mm OR micro metastases i.e. \>0.2-2mm)